Logo image of BVXV

BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:BVXV - US09073Q2049 - ADR

1.36 USD
+0.05 (+3.82%)
Last: 9/6/2023, 8:00:01 PM
1.38 USD
+0.02 (+1.47%)
After Hours: 9/6/2023, 8:00:01 PM

BVXV Key Statistics, Chart & Performance

Key Statistics
Market Cap4.97M
Revenue(TTM)N/A
Net Income(TTM)-10.92M
Shares3.65M
Float3.55M
52 Week High11.8
52 Week Low1.25
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-6.86
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2007-06-07
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


BVXV short term performance overview.The bars show the price performance of BVXV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

BVXV long term performance overview.The bars show the price performance of BVXV in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BVXV is 1.36 USD. In the past month the price increased by 2.26%. In the past year, price decreased by -87.02%.

BIONDVAX PHARMACEUTICALS-ADR / BVXV Daily stock chart

BVXV Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About BVXV

Company Profile

BVXV logo image BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.

Company Info

BIONDVAX PHARMACEUTICALS-ADR

Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus

JERUSALEM 74036 IL

CEO: Amir Reichman

Employees: 33

BVXV Company Website

Phone: 97289302529.0

BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ

What does BIONDVAX PHARMACEUTICALS-ADR do?

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.


What is the stock price of BIONDVAX PHARMACEUTICALS-ADR today?

The current stock price of BVXV is 1.36 USD. The price increased by 3.82% in the last trading session.


What is the dividend status of BIONDVAX PHARMACEUTICALS-ADR?

BVXV does not pay a dividend.


What is the ChartMill technical and fundamental rating of BVXV stock?

BVXV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the market capitalization of BVXV stock?

BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a market capitalization of 4.97M USD. This makes BVXV a Nano Cap stock.


What is the ownership structure of BIONDVAX PHARMACEUTICALS-ADR (BVXV)?

You can find the ownership structure of BIONDVAX PHARMACEUTICALS-ADR (BVXV) on the Ownership tab.


BVXV Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BVXV. When comparing the yearly performance of all stocks, BVXV is a bad performer in the overall market: 91.2% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BVXV Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BVXV. BVXV may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BVXV Financial Highlights

Over the last trailing twelve months BVXV reported a non-GAAP Earnings per Share(EPS) of -6.86. The EPS decreased by -93.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%45.5%
Sales Q2Q%N/A
EPS 1Y (TTM)-93.48%
Revenue 1Y (TTM)N/A

BVXV Forecast & Estimates

7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.


Analysts
Analysts82.86
Price Target39.78 (2825%)
EPS Next Y99.29%
Revenue Next YearN/A

BVXV Ownership

Ownership
Inst Owners6.93%
Ins Owners18.86%
Short Float %N/A
Short RatioN/A